Drug recall · August 25, 2021
GaviLyteTM - C PEG-3350 recall
Why: Failed Stability Specification; Out of specification for Osmolarity
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
GaviLyteTM - C PEG-3350 (240g) and Electrolytes for Oral Solution, USP with Flavor Pack Manufactured by Novel Laboratories, Inc. Somerset, NJ 08873, USA Manufactured for Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 NDC 43386-060-19
- Lots / codes
Lot S001133, exp 7/2022
- Quantity
- 20,814 bottles
- Company
- Novel Laboratories, Inc. d.b.a LUPIN, Somerset, NJ
- Distribution
- Nationwide
- Initiated
- July 29, 2021 · Voluntary: Firm initiated
- Classified
- August 13, 2021
- Reported
- August 25, 2021
- Ended
- November 14, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch GaviLyte-C
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.